$1.48 Million is the total value of ABG Innovation Capital Partners III GP Ltd's 5 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 16.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CSTL | CASTLE BIOSCIENCES INC | $877,000 | +18.8% | 33,626 | 0.0% | 59.46% | +8.3% | |
| AADI BIOSCIENCES INC | $377,000 | +14.6% | 26,666 | 0.0% | 25.56% | +4.4% | ||
| SYBX | SYNLOGIC INC | $196,000 | -17.3% | 205,906 | 0.0% | 13.29% | -24.6% | |
| IDRA | IDERA PHARMACEUTICALS INC | $21,000 | -19.2% | 56,250 | 0.0% | 1.42% | -26.4% | |
| GNCA | GENOCEA BIOSCIENCES INC | $4,000 | -33.3% | 375,000 | 0.0% | 0.27% | -39.2% | |
| Exit | NABRIVA THERAPEUTICS PLC | $0 | – | -45,849 | -100.0% | -0.60% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Fan Yu #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SYNLOGIC INC | 12 | Q3 2023 | 33.8% |
| AADI BIOSCIENCES INC | 9 | Q3 2023 | 37.2% |
| IDERA PHARMACEUTICALS INC | 9 | Q4 2022 | 2.4% |
| GENOCEA BIOSCIENCES INC | 8 | Q3 2022 | 32.1% |
| NABRIVA THERAPEUTICS PLC | 7 | Q2 2022 | 2.3% |
| CASTLE BIOSCIENCES INC | 6 | Q3 2023 | 77.2% |
| PULMONX CORP | 5 | Q4 2021 | 33.9% |
| AERPIO PHARMACEUTICALS INC | 3 | Q2 2021 | 2.3% |
| ATEA PHARMACEUTICALS INC | 2 | Q2 2021 | 91.0% |
| ATEA PHARMACEUTICALS INC | 1 | Q1 2021 | 80.1% |
View ABG Innovation Capital Partners III GP Ltd's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-11-15 |
View ABG Innovation Capital Partners III GP Ltd's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.